Across TCGA pan-cancer cohorts, GIGYF2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated GIGYF2 data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher GIGYF2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated GIGYF2 expression acts as an unfavorable survival marker, although some lineages such as COAD and PDAC show a favorable association.

COAD, PDAC, and HNSC are the cancer types where GIGYF2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	All	1.000	0.891	.026	12	view →
PDAC	DFS	Quartile	III,IV	0.742	0.302	.021	5	view →
HNSC	DFS	Quartile	III,IV	0.599	0.901	.026	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: GIGYF2 tumor-vs-normal RNA expression · all GIGYF2 data types